Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Rating Upgraded by Wall Street Zen

by · The Cerbat Gem

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) was upgraded by equities researchers at Wall Street Zen to a “sell” rating in a research report issued to clients and investors on Saturday.

Several other research analysts have also commented on the company. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Reviva Pharmaceuticals in a research report on Tuesday, December 23rd. Chardan Capital reissued a “buy” rating and set a $40.00 target price on shares of Reviva Pharmaceuticals in a research note on Monday, January 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Thursday, January 22nd. Finally, D. Boral Capital downgraded Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 5th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $66.67.

Read Our Latest Analysis on RVPH

Reviva Pharmaceuticals Stock Performance

NASDAQ:RVPH opened at $2.47 on Friday. Reviva Pharmaceuticals has a fifty-two week low of $2.37 and a fifty-two week high of $23.40. The company has a 50 day moving average price of $5.40 and a 200 day moving average price of $8.46. The stock has a market capitalization of $14.42 million, a P/E ratio of -0.27 and a beta of 0.10.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. 683 Capital Management LLC acquired a new position in Reviva Pharmaceuticals during the 2nd quarter worth $381,000. Persistent Asset Partners Ltd raised its position in Reviva Pharmaceuticals by 300.0% in the 2nd quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock valued at $244,000 after purchasing an additional 480,864 shares in the last quarter. XTX Topco Ltd boosted its stake in shares of Reviva Pharmaceuticals by 63.6% in the 4th quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock valued at $46,000 after buying an additional 63,893 shares during the period. NewEdge Advisors LLC purchased a new position in shares of Reviva Pharmaceuticals in the 1st quarter valued at about $58,000. Finally, Geode Capital Management LLC grew its position in shares of Reviva Pharmaceuticals by 6.9% during the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after buying an additional 29,063 shares in the last quarter. 63.18% of the stock is currently owned by hedge funds and other institutional investors.

Reviva Pharmaceuticals Company Profile

(Get Free Report)

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.

Featured Articles